Headquartered in Solana Beach, CA Fiscal year ends December NASDAQ: CLPT clearpointneuro.com
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. It sells clinical products to hospitals and neurosurgeons and provides drug development services to biopharma partners.
It reports revenue in three categories:
- **Biologics and drug delivery:** disposable products and services tied to customer-sponsored preclinical and clinical trials. This includes the SmartFlow Neuro Cannula, co-labeled with an approved gene therapy, and preclinical CRO services at ClearPoint Advanced Laboratories.
- **Neurosurgery navigation and therapy:** disposables for cases using the ClearPoint Navigation System, Prism laser therapy, the Velocity MRI power drill and the IRRAflow Active Fluid Exchange System. IRRAflow was acquired with IRRAS in November 2025 and is used for neurocritical care and intracranial fluid management.
- **Capital equipment and software:** reusable hardware, software and related services.
The company works with 60+ active pharma partners across 25+ clinical trials, with 10+ partner programs under FDA expedited review. Its installed base exceeds 175 active centers across North America, Europe, Asia and South America, and it holds regulatory clearances in 34 countries. Pipeline efforts include robotic navigation, focused ultrasound, AI-derived planning software and spine laser ablation. Updated
The loss per share narrowed and beat expectations, the first real sign that the IRRAS deal is paying off: revenue grew 36% while operating expenses rose just 23%. Revenue missed expectations, and management guides 2026 to $48 million to $50 million.
Pre-Market Stock Futures: Futures are trading higher as we get set to end what has been one of the wildest weeks on Wall Street in some time. After blowing through all-time highs…
Investors have become quite familiar with the Magnificent Seven, the group of tech giants that reshaped markets with their dominance in AI, cloud computing, and digital ecosystems by driving unprecedented growth. Initially…
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. It sells clinical products to hospitals and neurosurgeons and provides drug development services to biopharma partners.
The Wall Street consensus 12-month price target for CLPT is $21.50.
